Function determines structure in the vasculature: lessons from insulin resistance
Why the study?
Does reduced nitric oxide bioavailability drive microvascular rarefaction and structural changes in insulin-resistant obese Zucker rats?
Population
leptin receptor-deficient obese Zucker rats and their lean counterparts heterozygous for the mutation
Comparison
Tempol, l-NAME, or l-NAME plus hydralazine added… vs untreated OZR and LZR
Design
Editorial
Follow-up
4 weeks
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for NO-targeted microvascular therapy in insulin resistance; leaves open translation beyond rodent models.
Structured PICO
Does reduced nitric oxide bioavailability drive microvascular rarefaction and structural changes in insulin-resistant obese Zucker rats?
P
Population
leptin receptor-deficient obese Zucker rats (OZR) and their lean counterparts heterozygous for the mutation (LZR)
I
Intervention
Tempol (superoxide dismutase mimetic), l-NAME (nitric oxide synthase antagonist), or l-NAME plus hydralazine added to chow for 4 weeks
C
Comparator
untreated OZR and LZR
O
Outcome
microvessel density and structural features of resistance vesselssurrogate
This editorial highlights evidence that impaired nitric oxide bioavailability, rather than just hypertension or oxidant stress directly, is a primary driver of microvascular rarefaction in insulin resistance.
Limitations
- treatments were of insufficient duration to affect structural parameters
Cite This Study
Mather et al. (2005) studied this question.